HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) web only appendices All Versions of this Article: ard.2007.076174v1 67/6/741    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Google Scholar Articles by Kastrinaki, M-C Articles by Papadaki, H A PubMed PubMed Citation Articles by Kastrinaki, M-C Articles by Papadaki, H A

Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis

¹ Department of Haematology, University of Crete School of Medicine, Heraklion, Crete, Greece
² Department of Rheumatology, Clinical Immunology and Allergiology, University of Crete School of Medicine, Heraklion, Crete, Greece
³ Institut de Génétique Humaine, UPR1142 CNRS, Montpellier, France
⁴ Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Berlin, Germany
⁵ Equipe INSERM-ESPRI/EA-3855, Faculty of Medicine, University Francois Rabelais, Tours, France
⁶ Service d’Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France

Correspondence to:
H A Papadaki, University of Crete School of Medicine, P.O. Box 1352, Heraklion, Crete, Greece; epapadak{at}med.uoc.gr

Objective: Bone marrow (BM) mesenchymal stem cells (MSCs) are being considered as potential therapeutic agents in various inflammatory autoimmune diseases for their tissue-repair and anti-inflammatory tissue-protective properties. This study investigates the reserves and function, the molecular and proteomic profile and the differentiation potential of BM MSCs in patients with active rheumatoid arthritis (RA).

Methods: We evaluated the frequency of MSCs in the BM mononuclear cell fraction using a limiting dilution assay, the proliferative/clonogenic potential and the capacity of cells to differentiate towards the osteogenic/chondrogenic/adipogenic lineages using appropriate culture conditions. We also assessed the molecular and proteomic characteristics in terms of inflammatory cytokine gene and protein expression, the relative telomere length and the survival characteristics of BM MSCs.

Results: MSCs from patients with RA (n = 26) and age- and sex-matched healthy individuals (n = 21) were similar in frequency, differentiation potential, survival, immunophenotypic characteristics, and protein profile. Patient MSCs, however, had impaired clonogenic and proliferative potential in association with premature telomere length loss. Transcriptome analysis revealed differential expression of genes related to cell adhesion processes and cell cycle progression beyond the G1 phase. Previous treatment with methotrexate, corticosteroids, anti-cytokine and biological agents or other disease-modifying anti-inflammatory drugs did not correlate with the clonogenic and proliferative impairment of BM MSCs.

Conclusion: In spite of some restrictions related to the impaired clonogenic and proliferative potential, our findings support the use of autologous BM MSCs in RA and may have important implications for the ongoing efforts to repair tissue injury commonly seen in the course of the disease.